Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level Mr. Shah Coherent Market Insights Pvt.

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist ...

Patients with obesity and comorbid cardiovascular disease were more likely to ration prescription drugs than those without obesity.

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

The following is a summary of “Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention,” published in the ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.